Pfizer plans reorganisation and reshuffle

Pfizer, the world’s biggest drugmaker, said it will split up its three major internal businesses and shuffle the management that leads them, part of the company’s preparation for a further breakup.

Pfizer in 2012 sold its infant nutrition business to Nestle SA for $11.9bn (€8.97bn) and this year spun off its $4.3bn-a-year animal-health unit.

The latest reorganisation divides what’s left of the company into two brand-name drug units and a generics business, the company said in a statement.